Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04056195 · ClinicalTrials.gov registry record · Phase 2
Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)
A Phase 2 study, sponsored by Oscotec.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT04056195 is a Phase 2 study that has completed, run by Oscotec. The registered enrollment target is 61 participants.
The verdict
NCT04056195, a Phase 2 study, has completed, sponsored by Oscotec.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed to respond or relapsed after prior therapy, with a platelet count \<30,000/µL. Patient will be randomly assigned in 2 groups with two dose levels of SKI-O-703 200mg BID, 400 mg BID, and placebo; administered orally twice a day.
Interventions
- DRUG Placebo oral tablet
- DRUG SKI-O-703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-10-11 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04056195
The ClinicalTrials.gov registry entry for NCT04056195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oscotec, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04056195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04056195 about?
NCT04056195 is a clinical study titled "Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)". Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed to respond or relapsed after prior therapy, with a platelet count \<30,000/µL. Patient will be randomly assigned in 2 groups with two dose levels of SKI-O-703 200mg BID, 400 mg BID, and placebo; administered...
What is the current status of trial NCT04056195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2019-10-11. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT04056195?
The interventions under investigation include: Placebo oral tablet (DRUG), SKI-O-703 (DRUG).
Who is sponsoring clinical trial NCT04056195?
This trial is sponsored by Oscotec, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.